ScinoPharm Taiwan, Ltd.

Established in 1997, ScinoPharm Taiwan, Ltd. develops and manufactures active pharmaceutical ingredients and sterile injectable drug products for generic and innovative pharmaceutical companies. Its work centers on complex, high-barrier compounds for oncology, hematology, central nervous system, cardiovascular, metabolic, infectious, and orphan disease therapies. The company combines small-molecule and peptide development with formulation expertise for liquid and lyophilized injectables in vials, cartridges, and syringes. Its CDMO operations cover process development, technology transfer, clinical materials, analytical methods, regulatory CMC work, and commercial manufacturing, with particular depth in cytotoxic compounds, steroids, and peptides.

Manufacturing operations include 18 cGMP production lines equipped with reactors ranging from 20 to 10,000 liters and dedicated filtration, drying, micronization, and packaging equipment. The company applies liquid-phase and solid-phase peptide synthesis, segment condensation, tangential flow filtration, and chromatographic purification, with peptide capacity reaching 200 kilograms annually. Sterile injectable production uses single-use filtration and filling components and can handle cytotoxic, high-potency, and biologic products. Facilities in Taiwan and Changshu operate under a shared quality system reviewed by the US FDA, Japan PMDA, and other health authorities, while digital quality management, risk-based controls, and process hazard analysis underpin development and commercial production.